Use Novel ADME Tools to Improve Early Human PK Projection

Jonathan Grob, Ginkgo Bioworks

Jonathan is a Scientist, AI-enabled drug hunter and Platform Builder with nearly 25 years of experience across large pharma and biotech. He has led drug discovery technology efforts that integrate chemistry, biology and computation to accelerate the creation of novel medicines.

Before joining Ginkgo, Jonathan spent two decades at Novartis, contributing to multiple small-molecule programs from early discovery through lead optimization. He then served as Head of Early Discovery Chemistry at Valo, where he helped build and lead the AI-enabled, Closed-Loop Discovery platform that tightly connected chemistry, ADME, biology and data science to accelerate drug discovery programs.

Jonathan has authored numerous peer-reviewed publications and patents and is passionate about building collaborative, cross-functional teams at the intersection of science and technology.

Alex Taylor, Inductive Bio

Alex is a Medicinal Chemist passionate about drug discovery. Over almost two decades in the industry, he has contributed to more than a dozen development candidates, two of which have reached registrational trials in the clinic. Before joining Inductive Bio, Alex was the VP, Head of Chemistry at Relay Therapeutics, where the team integrated traditional medicinal chemistry approaches with predictive ADME and potency models to identify development candidates. He has worked across multiple small molecule classes and mechanisms of action, including reversible, covalent, chaperone, degrader and macrocyclic peptides. Alex got his start in the industry at Constellation Pharmaceuticals, applying fragment-based drug design to the creation of selective bromodomain inhibitors, in collaboration with Genentech.

Before becoming a Medicinal Chemist, Alex completed his PhD at Harvard University with Stuart Schreiber and was a postdoctoral fellow at MIT in Steve Buchwald’s lab. He did undergraduate research at Vanderbilt University with Ned Porter and was a Fulbright Scholar at the Universität Basel with Bernd Giese.

Ted Peters, Cofounder at Tangible Scientific

Ted Peters has built, staffed, and run compound management labs at some of Boston’s top biotechs — Millennium Pharmaceuticals, Constellation Pharmaceuticals, and Relay Therapeutics — and has advised companies across the Third Rock Ventures portfolio and the broader drug discovery community on standing up sample management operations of their own.

That career gives Ted an inside view of how compound management actually fits into a research program, and what scientists expect from it day to day. As Cofounder at Tangible Scientific, he puts that perspective to work building services that look and feel like an internal capability — held to the standard of quality and turnaround discovery teams would demand from their own labs.